About Us

Prior Transave Announcements

Insmed Incorporated and Transave, INC. Announce Business Combination

December 2, 2010

Arikace™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients

October 21, 2010

Arikace&trade Demonstrates Sustained Benefit in the Treatment of Scystic Fibrosis in Patients Who Have Pseudomonas Lung Infections

June 17, 2010

Transave Issued Key Composition of Matter for Arikace™

May 24, 2010

Transaave Completes Successful Phase II Clinical Program for Arikace™ in the Treatment of Pseudomonas Lung Infections

October 17, 2009

Transave Announces Positive Phase II Results for Once-Daily Arikace™ in the Treatment of Non-bronchiectasis Patients Who Have Pseudonomas Lung Infections

September 13, 2009

Transave Enters into Cooperative Research Agreement with NIH to Study Arikace™ in Nontuberculosis Mycobacteria

July 30, 2009

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of Arikace™

June 25, 2009

Transave Completes Enrollment in Arikace™ Phase II Bronchietctasis Study

April 21, 2009

Transave, Inc. Secures $12.5 Million in New Financing Strength of Phase II Data for LEad Drug Candidate Ariakce™ Drives Continued Clinical Expansion

October 2, 2008

Press Releases

Feb. 10, 2012
Insmed Incorporated Provides Update on Clinical Program for ARIKACE® Read More
Jan. 20, 2012
Insmed Incorporated Provides Corporate Update Read More